At Joinery, we specialize in the de novo design of peptides and macrocycles
We are a core member company of the Wyss Institute’s Diagnostic Accelerator at Harvard University and the Engineering Innovation Group at MIT.
We are an interdisciplinary group of creators with a shared vision
Our long-term goal is to prevent future pandemics by rapidly analyzing emergent infections, developing and manufacturing diagnostics to detect them, determining their threat level, and distributing diagnostics for random testing at densely populated venues such as airports, hotels, restaurants, hospitals, stadiums, theme parks, office buildings, army bases, and apartment buildings. Specifically, we will engineer therapeutic agents such as fusion inhibitors and molecular recognition elements.
TEAM
Greg Czyryca, CSO
Przemysław Greg Czyryca has a PhD in physial chemistry from the Lodz University of Technology. His research interests include rational drug design, artificial intelligence, and computational chemistry. In his prior work with Allosterix Pharmaceuticals, Dr. Czyryca has created a de novo design approach for macrocyclic peptides and ‘mini’ proteins, based on a mature evolutionary algorithm, that has been applied to design immune checkpoint modulators, viral attachment inhibitors, and other "undruggable" targets.
Lexington Blood, COO
Lexington’s education includes Biochemistry and Physics at the University of Utah, Machine Learning and Financial Engineering at Stanford and Columbia. He is a partner at the global venture capital fund 7BC, GP of a Quant Hedge Fund, and a partner at Harvard's Wyss Institute Diagnostics Accelerator for Biologically Inspired Design. He is a passionate humanitarian, a UNESCO Peace Fellow and Advisor to a Broad Institute Cancer Genomic Data Collective at MIT and Harvard.